569BCFB6-7B4D-459A-962A-4C148889CE2C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.842312746386334
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.543
- G2M_CHECKPOINT+0.507
- MYC_TARGETS_V2+0.498
- MYC_TARGETS_V1+0.462
- DNA_REPAIR+0.461
- NOTCH_SIGNALING+0.421
- ANGIOGENESIS+0.417
- WNT_BETA_CATENIN_SIGNALING+0.407
- INTERFERON_ALPHA_RESPONSE+0.384
- UNFOLDED_PROTEIN_RESPONSE+0.317
Top 10 suppressed
- KRAS_SIGNALING_DN-0.360
- PANCREAS_BETA_CELLS-0.201
- SPERMATOGENESIS-0.188
- ESTROGEN_RESPONSE_EARLY-0.182
- INFLAMMATORY_RESPONSE-0.180
- MYOGENESIS-0.145
- HEDGEHOG_SIGNALING-0.136
- APICAL_SURFACE-0.114
- ESTROGEN_RESPONSE_LATE-0.096
- IL6_JAK_STAT3_SIGNALING-0.077
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934817 | — | — | 0.934 |
| 2 | 4FE5EDE2-7790-4A75-9BB6-93260A8154A0 | — | — | 0.929 |
| 3 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.916 |
| 4 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.914 |
| 5 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.911 |
| 6 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.900 |
| 7 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.898 |
| 8 | 3941F338-3165-4CCA-9108-65A110186E6B | — | — | 0.898 |
| 9 | 2F382D6A-B26F-450A-A156-9407D14538CD | — | — | 0.897 |
| 10 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.543 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.507 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.498 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.462 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.461 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.421 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.417 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.407 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.384 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.317 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.309 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.299 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.299 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.293 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.275 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.273 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.264 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.243 | Inavolisib | — uncovered |
| APOPTOSIS | 0.235 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |